Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

Organization National Institutes of HealthPosted 18 Nov 2024Deadline 7 Jan 2027
HHS-NIH1193.393synopsis
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Opportunity Number: PAR-25-070 Document Type: synopsis CFDA Numbers: 93.393

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →